Bootstrap Bio and Manhattan Genomics, two companies focused on human embryo editing to prevent genetic diseases, have ceased operations. The closures mark a setback for the controversial field of germline editing.
Bootstrap Bio and Manhattan Genomics have both shut down their operations, ending their respective efforts to develop human embryo editing technologies. The companies were among a small number of firms pursuing germline editing—modifications to embryos that would be inherited by future generations—primarily to prevent serious genetic conditions.
The reasons behind the closures were not immediately detailed, but the exits underscore the commercial and regulatory challenges facing the embryo editing sector. The field has faced intense scrutiny from bioethicists, policymakers, and the public since Chinese scientist He Jiankui's 2018 announcement of the first gene-edited babies, which triggered global controversy and criminal charges against him.
The U.S. and many other countries have restricted or banned germline editing in humans. While some researchers continue work on somatic gene therapy—editing non-reproductive cells—the commercial viability of human embryo editing remains highly uncertain.
Amsterdam-based Monumental secured a $32 million Series B round led by Khosla Ventures. The company develops autonomous robotics and AI software for the construction industry.
Indian AI coding startup Emergent reached a $1.5 billion valuation in its latest funding round, raising $130 million in Series C and joining the unicorn club after a five-fold valuation jump in six months.
Rime, an AI platform processing over 100 million calls monthly, secured $24 million in Series A funding to expand its customer service solutions for enterprises.
A former SpaceX engineer has secured $65 million in funding to revolutionize wire harness manufacturing for aerospace and defense. The startup aims to replace decades-old production methods still used in rockets, missiles, and satellites.